Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAM | P19021 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13142863 | 0.93 | MAPT (0.37) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL13179881 | 0.86 | PAM (0.33) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL13142865 | 0.86 | KDM4E (0.47) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL16405366 | 0.84 | PAM (0.34) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL16405365 | 0.83 | KDM4E (0.38) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL14789044 | 0.83 | PAM (0.39) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL23143030 | 0.79 | MAPT (0.39) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL13179780 | 0.79 | PAM (0.36) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL2466567 | 0.78 | PAM (0.38) | PAMKDM4EMAPTTHRBALOX15 | |
| SCHEMBL10564990 | 0.75 | MAPT (0.42) | PAMKDM4EMAPTTHRBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2015-01-22 | — | — | US | disclosed |
| US-8575217-B2 | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-11-05 | — | — | US | disclosed |
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2013-10-24 | — | — | US | disclosed |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | GENMEDICA THERAPEUTICS SL (ES) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281520-A1 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | PAM 2094/4885KDM4E 3003/4885MAPT 3367/4885 |
| US-20100234452-A1 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | HSD17B14, SORD, GPX4 | PAM 2094/4885KDM4E 3003/4885MAPT 3367/4885 |
| US-20150025006-A1 | Pharmaceutical Combinations Including Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders | IAPP, AMY2A, GPR119 | PAM 1015/4885KDM4E 4229/4885MAPT 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.